Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Deferred Revenue: 2015-2021

Historic Current Deferred Revenue for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Sep 2021 value amounting to $12.4 million.

  • Syndax Pharmaceuticals' Current Deferred Revenue rose 717.40% to $12.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $12.4 million, marking a year-over-year increase of 717.40%. This contributed to the annual value of $1.5 million for FY2020, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2021, Syndax Pharmaceuticals' Current Deferred Revenue is $12.4 million, which was up 717.40% from $1.5 million recorded in Q2 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' Current Deferred Revenue peaked at $12.4 million during Q3 2021, and registered a low of $1.2 million during Q1 2017.
  • Moreover, its 3-year median value for Current Deferred Revenue was $1.5 million (2021), whereas its average is $2.5 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Current Deferred Revenue dropped by 3.56% in 2018, and later spiked by 717.40% in 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $1.6 million in 2017, then decreased by 3.56% to $1.5 million in 2018, then remained steady at $1.5 million in 2019, then remained steady at $1.5 million in 2020, then skyrocketed by 717.40% to $12.4 million in 2021.
  • Its last three reported values are $12.4 million in Q3 2021, $1.5 million for Q2 2021, and $1.5 million during Q1 2021.